Tier 3 — preclinical

Macrophage SIRT6 promotes allergic airway inflammation through ATG3 deacetylation-mediated autophagy

Yuting Lei, Zhilin Xiong, Mengting Zhang, Shihai Li, Guomei Su, Ruina Huang, Jielin Duan, Xiao Gao, Tianwen Lai
Mucosal Immunology 2026 19(3):100335

Bibliography

PubMed
PMID 41864241
Competing interests
Authors declared no known competing financial interests or personal relationships.

Study snapshot

DesignMurine allergic-airway-inflammation study with myeloid-specific Sirt6 deletion and macrophage mechanistic experiments.
ModelAsthmatic mice and macrophages.
SampleMultiple animal and cellular experiments; exact group sizes not stated in indexed abstract.
InterventionMyeloid Sirt6 deletion and OSS-128167 pharmacological SIRT6 inhibition.
DurationModel-specific.
EndpointsAirway inflammation; Pro-inflammatory cytokines; ATG3 K77 deacetylation; Autophagy; Response to SIRT6 inhibition

What the study showed, in plain terms

In allergic airway inflammation, SIRT6 had the opposite role from the anti-inflammatory story seen in many aging models. Macrophage SIRT6 deacetylated ATG3, increased autophagy and promoted inflammatory cytokine production; deleting or inhibiting SIRT6 reduced inflammation.

Key findings

Myeloid-specific Sirt6 deletion attenuated allergic airway inflammation, while pharmacological SIRT6 inhibition with OSS-128167 suppressed macrophage autophagy and inflammation.

What this study can and cannot tell us

This is a disease- and cell-type-specific mouse mechanism. It does not show that systemic SIRT6 activation is broadly pro-inflammatory in humans, but it is critical counter-evidence against universal anti-inflammatory claims.

Citation network

Articles citing this research paper

5 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified